All AbMole products are for research use only, cannot be used for human consumption.
Stattic is the first nonpeptidic STAT3 inhibitor, potently inhibits STAT3 activation and nuclear translocation with IC50 of 5.1 μM, highly selectivity over STAT1. Stattic inhibits STAT3 phosphorylation (at Y705 and S727).
Cell Mol Immunol. 2023 Jun 12.
A subpopulation of CD146+ macrophages enhances antitumor immunity by activating the NLRP3 inflammasome
Stattic purchased from AbMole
Adv Sci (Weinh). 2022 Mar 8;e2103719.
CD146 Associates with Gp130 to Control a Macrophage Pro‐inflammatory Program That Regulates the Metabolic Response to Obesity
Stattic purchased from AbMole
Front Immunol. 2022 May 23;13:866638.
A Novel STAT3 Gain-of-Function Mutation in Fatal Infancy-Onset Interstitial Lung Disease
Stattic purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | Ly3 cells |
| Preparation method | MTS |
| Concentrations | ~2.5 μM |
| Incubation time | 48 h |
| Animal Experiment | |
|---|---|
| Animal models | Ly3 parental NOD/SCID IL2R null xenograft |
| Formulation | |
| Dosages | 3.75 mg/kg every day |
| Administration | i.p. |
| Molecular Weight | 211.19 |
| Formula | C8H5NO4S |
| CAS Number | 19983-44-9 |
| Solubility (25°C) | DMSO 40 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Sijia Li, et al. Stattic alleviates acute hepatic damage induced by LPS/d-galactosamine in mice
[5] Jochen Schust, et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization
| Related STAT Products |
|---|
| HP590
HP590 is an orally active, novel and potent STAT3 inhibitor (STAT3 luciferase activity: IC50=27.8 nM; ATP inhibition: IC50=24.7 nM). |
| 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea
STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. |
| HJC0123
HJC0123 is a novel STAT3 inhibitor that suppresses the fibrogenic properties of HSCs. HJC0123 reduced the phosphorylation, nuclear translocation, and transcriptional activity of STAT3. HJC0123 treatment resulted in the inhibition of HSCs proliferation at submicromolar concentrations. It decreased the expression of STAT3-regulated proteins, induced cell cycle arrest, promoted apoptosis and downregulated SOCS3. |
| ODZ10117
ODZ10117 is a small molecule inhibitor of STAT3. ODZ10117 inhibited migration and invasion and induced apoptotic cell death by targeting STAT3 in glioblastoma cells. |
| OPB-111077
OPB-111077 is a first-in-class, novel, oral inhibitor of STAT3 and mitochondrial oxidative phosphorylation (OXPHOS) with anticancer activity. OPB-111077 inhibits mitochondrial respiratory chain complex I, which leads to inhibition of energy production and activation of the AMPK-mTOR energy stress sensor pathway. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
